SecBot SecBot
6-K ·Filed Jun 15, 2026

GSK

GSK plc
NEUTRAL
Impact 3/10
Horizonimmediate Processed5mo ago SEC0001654954-26-005975
Notable filing: 6-K
Actionable Insight • Neutral

This filing confirms GSK is steadily executing its existing buyback program. No new authorization or change in pace is indicated. Traders should monitor future 6-K filings for cumulative buyback progress and any updates to the program's size or duration.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$52.23
T+0 close · Jun 15, 2026 · via day close
Latest settled
−6.89%
T+60 · $48.63
Vs SPY
−7.90%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 15 $52.23entry
  2. T+1 · 5mo ago −0.02%α +0.58% · $52.22
  3. T+5 · 5mo ago −2.85%α −1.47% · $50.74
  4. T+20 · 4mo ago +0.11%α +0.86% · $52.29
  5. T+60 · 2mo ago −6.89%α −7.90% · $48.63
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

GSK filed a routine 6-K disclosing weekly share repurchases under its existing buyback program. The company bought ~1.1M shares over five days in June 2026 at an average price of ~1,930 GBp, continuing the program announced on May 11, 2026. This is a standard periodic update with no new strategic or financial information.

Key Facts

  • Purchased 225,237 shares on June 8, 228,524 on June 9, 222,449 on June 10, 220,242 on June 11, and 215,972 on June 12, 2026.
  • Volume-weighted average prices ranged from 1,882.23 GBp to 1,983.00 GBp per share.
  • Since May 11, 2026, GSK has repurchased a total of 7,346,236 ordinary shares.
  • After these purchases, GSK holds 268,724,522 shares in treasury (6.64% of voting rights) and has 4,047,527,077 shares in issue (excluding treasury).

Financial Impact

Approximately £21.2M spent on repurchases during the reported week (based on VWAP and share counts), representing ~0.02% of market cap. Cumulative program spend since May 11 is not disclosed but is a fraction of the overall buyback authorization.

shares outstandingtreasury sharesvoting rights

Risk Factors

  • None material from this filing; buyback execution is routine and within announced parameters.

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
44% bullish (32 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001654954-26-005975
Document: 0001654954-26-005975-index-headers.html0001654954-26-005975
Document: 0001654954-26-005975-index.html0001654954-26-005975
Document: 0001654954-26-005975.txt0001654954-26-005975

US Market Status

Market Closed · Opens Wed (10h 35m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 15, 2026